Blastomycosis

Hospital and Clinical Pharmacy Preferred Distribution Channels for Blastomycosis Drugs: Market Insights and Regional Analysis - ResearchAndMarkets.com

Retrieved on: 
Montag, August 14, 2023
General Health, Infectious Diseases, Hospitals, Health, Pharmaceutical, Infection, Fungal infection, Prevalence, Blastomycosis, Medicine, Spore, Wood, Incidence, Soil, Patient, Tuberculosis, Azole, Chrysosporium, Geography, Conditional sentence, Growth, Immunodeficiency, Pneumonia, Pharmaceutical industry

The "Blastomycosis Market by Drug Type, Distribution Channel, Formulation, and Geography: Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blastomycosis Market by Drug Type, Distribution Channel, Formulation, and Geography: Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.
  • This report provides a comprehensive analysis of the market for the treatment of blastomycosis, a fungal infection caused by Blastomyces dermatitidis.
  • Blastomycosis is a fungal infection caused by the organism Blastomyces dermatitidis, which grows in wood and soil.
  • The blastomycosis market is segmented based on drug type, distribution channel, formulation, and geography.

Global Invasive Fungal Infections Market Report 2023: Increasing Invasive Fungal Infections with Life-threatening Conditions Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Montag, Mai 29, 2023
Biotechnology, Pharmaceutical, Health, Molecule, Amphotericin B, Fungal infection, Risk factor, Imidazole, Prevalence, Diabetes, HIV, Blastomycosis, Posaconazole, Infection, Candidiasis, Overalls, Isavuconazonium, Ageing, Mucormycosis, Merck & Co., Polyene, Fungemia, CDC, Incidence, AR, Patient, Developed country, ROW, Growth, Mortality, Merck, Immunodeficiency, Immunosuppression, Cryptococcus, Pfizer, Triazole, Pharmaceutical industry, Vaccine, Voriconazole, Echinocandin, Aspergillosis, Azole, Fluconazole

However, there are also antibody molecules in early preclinical development, which are currently not on the market.

Key Points: 
  • However, there are also antibody molecules in early preclinical development, which are currently not on the market.
  • The increasing use of broad-spectrum antibiotics, the aging population, and the growing prevalence of immunocompromised patients are driving the growth of invasive candidiasis.
  • By Region: The report provides insight into the invasive fungal infections market based on the geographical operations, namely North America, Europe, Asia Pacific, and ROW.
  • The North American region has emerged as a dominant player in the invasive fungal infections market, owing to several key factors.

USW Calls on Paper Industry to Institute Safeguards Against Deadly Fungal Infection

Retrieved on: 
Samstag, April 15, 2023
Infection, Disease, Metal, Friends, Blastomycosis, USW, Table tennis rubber, Multimedia, Public sector, Wood, United Steelworkers, Soil, Mining, Paper, Family, Glass, Recycling

Rather than waiting to see if cases develop at other paper mills, management across the industry must be proactive and institute robust safeguards now."

Key Points: 
  • Rather than waiting to see if cases develop at other paper mills, management across the industry must be proactive and institute robust safeguards now."
  • The Escanaba mill, owned by Billerud, is currently idled while it undergoes deep cleaning.
  • The USW is working with management and national health and safety officials to determine the precise source of the outbreak and ensure workers receive appropriate treatment.
  • "The paper industry involves a number of potentially serious hazards, but we've made incredible progress in making it safer," said USW International Vice President Leeann Foster, who leads bargaining in the USW's paper sector.

$25+ Billion Antifungal Drugs Markets, 2030 by Drug Class, Infection Type, Therapeutic Indications, Dosage Forms - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, September 8, 2022
Health, General Health, Conditional sentence, Candidiasis, Polyene, Form, Dermatophytosis, CDC, Disease, Death, Incidence, Infection, Gilead Sciences, Skin, Merz Pharma, Bloodstream infections, Pfizer, Mycosis, Center, Azole, Prevalence, CAGR, Population, Immunodeficiency, Centers for Disease Control and Prevention, Bayer, Echinocandin, Johnson & Johnson, Tuberculosis, Abbott Laboratories, Diabetes, Blastomycosis, Growth, Drug development, Region, Environment, Patient, Pharmaceutical industry, Fine chemical, Aspergillosis

The "Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR of 3.9% from 2021 to 2030.
  • Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.
  • The antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region.

TNF Alpha Inhibitors Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Montag, August 1, 2022
Health, Pharmaceutical, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Certolizumab pegol, Warfarin necrosis, Etanercept, IBD, Immune-mediated inflammatory diseases, Inflammation, Infliximab, Tuberculosis, UC, TNF, Dermatology, Food, Blastomycosis, Rheumatoid arthritis, Janssen Biotech, Crohn's disease, Ulcerative colitis, Tumor necrosis factor, Histoplasmosis, AbbVie, Disease, Inflammatory bowel disease, Rheumatology, Person, Eastman Kodak Co. v. Image Technical Services, Inc., Gastroenterology, Pfizer, Ankylosing spondylitis, Hepatitis, Candidiasis, RA, TNA, FDA, Spondyloarthropathy, Patient, Psoriasis, Adalimumab, Overalls, Growth, Infection, Neutropenia, Amgen, Prevalence, UCB, Pharmaceutical industry, Lithium, Ablynx

The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering.
  • The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-a) inhibitors by entities that manufacture TNF alpha inhibitors.
  • The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market.
  • Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

TNF Alpha Inhibitors Global Markets Research Report 2021: Focus on Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), & Simponi (golimumab) - ResearchAndMarkets.com

Retrieved on: 
Montag, Dezember 6, 2021
Health, Pharmaceutical, Patient, Growth, Ankylosing spondylitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Psoriasis, Crohn's disease, Rheumatology, Hepatitis, Inflammation, Overalls, Tuberculosis, Rheumatoid arthritis, Adalimumab, Neutropenia, Candidiasis, Prevalence, Dermatology, Histoplasmosis, Janssen Biotech, Etanercept, District Co-operative Central Bank, AbbVie, Pfizer, Warfarin necrosis, RA, Food, COVID-19, IBD, Infliximab, UCB, Inflammatory bowel disease, UC, Certolizumab pegol, Ulcerative colitis, Blastomycosis, Infection, Amgen, FDA, Tumor necrosis factor, TNA, Spondyloarthropathy, Gastroenterology, TNF, Immune-mediated inflammatory diseases, Pharmaceutical industry

The "TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-?)
  • The TNF alpha inhibitors market covered in this report is segmented by drug into remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), simponi (golimumab).
  • The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market.

SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Retrieved on: 
Mittwoch, Januar 8, 2020
Infectious diseases, Animal diseases, Medical specialties, Histoplasmosis, Zoonoses, Aspergillosis, Coccidioidomycosis, Mycosis, Blastomycosis

The FURI study protocol was recently amended to also include patients with aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other emerging, difficult-to-treat fungal infections.

Key Points: 
  • The FURI study protocol was recently amended to also include patients with aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other emerging, difficult-to-treat fungal infections.
  • One patient with an ongoing fungal infection died while on study drug due to an underlying condition.
  • "The positive results from this second interim analysis are fully consistent with the positive outcomes observed in the first interim analysis," said David Angulo, MD., Chief Medical Officer of SCYNEXIS.
  • "Patients enrolled in the FURI study typically suffer from complex underlying medical conditions, aggravated by a severe fungal infection.